MDCX

Medicus Pharma Ltd

• TipRanks·1d ago

  Medicus Pharma enters media partnership with New to The Street

• TipRanks·2d ago

  Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market

• TipRanks·2d ago

  Medicus Pharma submits clinical study design to FDA for Teverelix

• Reuters·2d ago

  Medicus submits optimized Teverelix Phase 2 protocol to FDA for AUR recurrence prevention

• Reuters·2d ago

  MEDICUS PHARMA SUBMITS OPTIMIZED PHASE 2 STUDY PROTOCOL TO U.S. FDA FOR TEVERELIX IN ACUTE URINARY RETENTION

• TipRanks·04/01 15:10

  Medicus Pharma Sharpens SkinJect Phase 2 Narrative, Pivots to 200µg Dose for Registrational Path

• Reuters·04/01 11:33

  Medicus clarifies SkinJect Phase 2 results, says 200µg dose leads registrational plan

• Reuters·04/01 11:32

  Medicus clarifies SkinJect Phase 2 topline, downplays device-only arm in development path

• Reuters·04/01 11:30

  MEDICUS PHARMA: PHASE 2 STUDY IS "PROOF OF CONCEPT" EXPLORATORY STUDY, PRIMARILY FOCUSED ON ACHIEVING MEANINGFUL CLINICAL (VISUAL) CLEARANCE

• Reuters·04/01 11:30

  MEDICUS PHARMA LTD - DATASET SUPPORTS SKINJECT DEVELOPMENT, REGULATORY DISCUSSIONS, AND STRATEGIC PARTNERSHIPS

• Reuters·04/01 11:30

  MEDICUS PHARMA LTD CLARIFIES POSITIVE SKINJECT PHASE 2 DATASET

• Reuters·04/01 11:30

  MEDICUS PHARMA LTD - DEVELOPMENT FOCUS IS ON ACTIVE TREATMENT ARMS IN PHASE 2 STUDY

• TipRanks·03/31 17:40

  Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Butterfly Network (BFLY)

• TipRanks·03/30 15:22

  Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate

• TipRanks·03/30 15:16

  Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2